Trial reportGastroenterology2008
A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults.
Trial report in Gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Comparing the reporting and conduct quality of exercise and pharmacological randomised controlled trials: a systematic review.BMJ open · 2021Pooled it
- Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy.Gastroenterology · 2015Trial
- Impact of GNB3-C825T, ADRB3-Trp64Arg, UCP2-3'UTR 45 bp del/ins, and PPARγ-Pro12Ala polymorphisms on Bofutsushosan response in obese subjects: a randomized, double-blind, placebo-controlled trial.Journal of medicinal food · 2014Trial
- A preliminary candidate genotype-intermediate phenotype study of satiation and gastric motor function in obesity.Obesity (Silver Spring, Md.) · 2010Trial
- Brain serotonin transporter occupancy by oral sibutramine dosed to steady state: a PET study using (11)C-DASB in healthy humans.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2010Trial
- Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM).Archives of endocrinology and metabolism · 2024Review
- Individualised prescription of medications for treatment of obesity in adults.Reviews in endocrine & metabolic disorders · 2023Review
- The Niche of n-of-1 Trials in Precision Medicine for Weight Loss and Obesity Treatment: Back to the Future.Current nutrition reports · 2022Review
- Adrenergic receptors gene polymorphisms and autonomic nervous control of heart and vascular tone.Physiological research · 2021Review
- The importance of gene-environment interactions in human obesity.Clinical science (London, England : 1979) · 2016Review
- Comparison Between Marital Satisfaction and Self-Esteem Before and After Bariatric Surgery in Patients With Obesity.Iranian journal of psychiatry and behavioral sciences · 2016Article
- Influence of G-protein β-Polypeptide 3 C825T Polymorphism on Antihypertensive Response to Telmisartan and Amlodipine in Chinese Patients.Chinese medical journal · 2016Article
- Association of the C825T polymorphism in the GNB3 gene with obesity and metabolic phenotypes in a Taiwanese population.Genes & nutrition · 2013Article
- Assessing gene-gene interactions in pharmacogenomics.Molecular diagnosis & therapy · 2012Review
- Association of genetic variation in cannabinoid mechanisms and gastric motor functions and satiation in overweight and obesity.Neurogastroenterology and motility · 2011Article
- Association of TCF7L2 allelic variations with gastric function, satiation, and GLP-1 levels.Clinical and translational science · 2011Article
- Genetics of Obesity: What have we Learned?Current genomics · 2011Article
- Predictors of weight loss and maintenance in patients treated with antiobesity drugs.Diabetes, metabolic syndrome and obesity : targets and therapy · 2011Article
- Genetics of type 2 diabetes.Current opinion in clinical nutrition and metabolic care · 2010Review
- Effect of the common -866G/A polymorphism of the uncoupling protein 2 gene on weight loss and body composition under sibutramine therapy in an obese Taiwanese population.Molecular diagnosis & therapy · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsWeight loss in response to sibutramine is highly variable. We assessed the association of specific markers of polymorphisms of candidate alpha2A adrenoreceptor, 5-HT transporter, and GNbeta3 genes and weight loss with sibutramine.
methodsWe conducted a randomized, double-blind, pharmacogenetic study of behavioral therapy and sibutramine (10 or 15 mg daily) or placebo for 12 weeks in 181 overweight or obese participants. We measured body weight, body mass index, body composition, gastric emptying, and genetic variation (alpha2A C1291G, 5-HTTLPR, and GNbeta3 C825T genotypes). Analysis of covariance was used to assess treatment effects on and associations of the specific markers of candidate genes with weight loss and body composition.
resultsSibutramine, 10 and 15 mg, caused weight loss (P = .009); there was a statistically significant gene by dose interaction for GNbeta3 genotype. For each candidate gene, significant treatment effects at 12 weeks were observed (P < .017) for all specific genotype variants (Delta weight loss in the 2 sibutramine doses vs placebo): alpha2A CC (Delta, approximately 5 kg), GNbeta3 TC/TT (Delta, approximately 6 kg), and 5-HTTLPR LS/SS (Delta, approximately 4.5 kg). Gene pairs resulted in significantly greater sibutramine treatment effects on weight (both P < .002): in participants with 5-HTTLPR LS/SS with GNbeta3 TC/TT; Delta, approximately 6 kg and those with alpha2A CC with GNbeta3 TC/TT; Delta, approximately 8 kg; however, effects were not synergistic. Treatment with sibutramine also resulted in significantly greater reduction of body fat for specific alpha2A CC and GNbeta3 TC/TT genotype variants individually (both P < .02).
conclusionsPatient selection based on candidate genes may enhance response to multidimensional sibutramine and behavioral therapy for obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.